High‐throughput sequencing detection and ensartinib treatment of lung cancer harboring NTRK1 fusion

High‐throughput sequencing detection and ensartinib treatment of lung cancer harboring NTRK1 fusion

Bibliographic Details
Main Authors:	Zhengbo Song, Chunwei Xu, Xingxiang Pu, Youcai Zhu, Wenxian Wang, Xingliang Li, Yanqiu Gao, Wenliang Zhu, Yunwei He, Lin Wu, Li Mao, Li Chen, Ming Chen
Format:	Article
Language:	English
Published:	Wiley 2021-02-01
Series:	Cancer Communications
Online Access:	https://doi.org/10.1002/cac2.12133

Similar Items

Molecular and clinicopathologic features of gliomas harboring NTRK fusions
by: Matthew Torre, et al.
Published: (2020-07-01)

Pharmacology and Clinical Evaluation of Ensartinib Hydrochloride Capsule
by: Yang WANG, et al.
Published: (2020-08-01)

ROS1-ADGRG6: a case report of a novel ROS1 oncogenic fusion variant in lung adenocarcinoma and the response to crizotinib
by: Shuguang Xu, et al.
Published: (2019-08-01)

Antitumor Activity of Larotrectinib in Tumors Harboring NTRK Gene Fusions: A Short Review on the Current Evidence [Corrigendum]
by: Ricciuti B, et al.
Published: (2020-05-01)

Antitumor activity of larotrectinib in tumors harboring NTRK gene fusions: a short review on the current evidence
by: Ricciuti B, et al.
Published: (2019-04-01)

NTRK fusion in Japanese colorectal adenocarcinomas
by: Yuya Yamashiro, et al.
Published: (2021-03-01)

NTRK1 fusion in glioblastoma multiforme.
by: Jinkuk Kim, et al.
Published: (2014-01-01)

Correction: NTRK1 Fusion in Glioblastoma Multiforme
by: The Staff
Published: (2014-01-01)

Successful Treatment with Ensartinib After Alectinib-induced Hyperbilirubinemia in ALK-Positive NSCLC
by: Peng L, et al.
Published: (2021-05-01)

Complete response to larotrectinib treatment in a patient with papillary thyroid cancer harboring an ETV6‐NTRK3 gene fusion
by: Fabián Pitoia
Published: (2021-04-01)

Identification of NTRK gene fusions in lung adenocarcinomas in the Chinese population
by: Ruiying Zhao, et al.
Published: (2021-07-01)

Clinicopathological findings of pediatric NTRK fusion mesenchymal tumors
by: Jeongwan Kang, et al.
Published: (2020-09-01)

NTRK fusions in osteosarcoma are rare and non‐functional events
by: Baptiste Ameline, et al.
Published: (2020-04-01)

A primary undifferentiated pleomorphic sarcoma of the lumbosacral region harboring a LMNA-NTRK1 gene fusion with durable clinical response to crizotinib: a case report
by: Ning Zhou, et al.
Published: (2018-08-01)

Real-World Experience of NTRK Fusion-Positive Thyroid Cancer
by: Ashok, A., et al.
Published: (2022)

How I treat NTRK gene fusion-positive cancers
by: Ulrik Lassen
Published: (2019-05-01)

P-glycoprotein Mediates Resistance to the Anaplastic Lymphoma Kinase Inhiitor Ensartinib in Cancer Cells
by: Ambudkar, S.V, et al.
Published: (2022)

Recurrent EGFR alterations in NTRK3 fusion negative congenital mesoblastic nephroma
by: Li Lei, et al.
Published: (2020-08-01)

Evaluation of NTRK Gene Fusion by Five Different Platforms in Triple-Negative Breast Carcinoma
by: Shafei Wu, et al.
Published: (2021-08-01)

Complete response to crizotinib in a metastatic adenocarcinoma of unknown primary harboring MET amplification and NTRK1 co-occurring mutation
by: Yao J, et al.
Published: (2019-05-01)

Applicability of pan-TRK immunohistochemistry for identification of NTRK fusions in lung carcinoma
by: Simon Strohmeier, et al.
Published: (2021-05-01)

NTRK Fusions and TRK Inhibitors: Potential Targeted Therapies for Adult Glioblastoma
by: Yuekun Wang, et al.
Published: (2020-11-01)

Molecular characterization of the ETV6-NTRK3 fusion in congenital fibrosarcoma
by: Wai, Daniel Hon-Hei
Published: (2009)

Molecular characterization of the ETV6-NTRK3 fusion in congenital fibrosarcoma
by: Wai, Daniel Hon-Hei
Published: (2009)

<i>NTRK</i> Fusions in Sarcomas: Diagnostic Challenges and Clinical Aspects
by: Vasiliki Siozopoulou, et al.
Published: (2021-03-01)

Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers
by: Tingting Jiang, et al.
Published: (2021-02-01)

NTRK Fusions, from the Diagnostic Algorithm to Innovative Treatment in the Era of Precision Medicine
by: Federica Zito Marino, et al.
Published: (2020-05-01)

MLH1/PMS2 Expression Could Tell Classical NTRK Fusion in Fluorescence In Situ Hybridization Positive Colorectal Carcinomas
by: Yao Fu, et al.
Published: (2021-04-01)

<i>NTRK</i> Fusion Genes in Thyroid Carcinomas: Clinicopathological Characteristics and Their Impacts on Prognosis
by: Barbora Pekova, et al.
Published: (2021-04-01)

Clinical and radiographic response following targeting of BCAN-NTRK1 fusion in glioneuronal tumor
by: Christopher Alvarez-Breckenridge, et al.
Published: (2017-03-01)

Association of anaplastic lymphoma kinase variants and alterations with ensartinib response duration in non‐small cell lung cancer
by: Donghui Hou, et al.
Published: (2021-09-01)

NTRK-A narrative review
by: Ullas Batra, et al.
Published: (2021-01-01)

Precision medicine and its implementation in patients with NTRK fusion genes: perspective from developing countries
by: Andrés F. Cardona, et al.
Published: (2020-07-01)

<i>NTRK</i> Fusions in Central Nervous System Tumors: A Rare, but Worthy Target
by: Alessandro Gambella, et al.
Published: (2020-01-01)

Cytoplasmic TrkA Expression as a Screen for Detecting NTRK1 Fusions in Colorectal Cancer
by: Yuri Choi, et al.
Published: (2018-06-01)

Primary Resistance to Brigatinib in a Patient with Lung Adenocarcinoma Harboring ALK G1202R Mutation and LIPI-NTRK1 Rearrangement
by: Xiao Z, et al.
Published: (2020-05-01)

Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors
by: Liu D, et al.
Published: (2018-07-01)

Characterization of a newly identified ETV6-NTRK3 fusion transcript in acute myeloid leukemia
by: Erdel Martin, et al.
Published: (2011-03-01)

Mammary analogue secretory carcinoma of the salivary gland with NTRK fusions: new approaches for diagnostics and targeted therapy (review)
by: A. V. Ignatova, et al.
Published: (2020-07-01)

KANK1-NTRK3 fusions define a subset of BRAF mutation negative renal metanephric adenomas
by: Aida Catic, et al.
Published: (2020-10-01)